Evidence map›Paper›PMID 25894242›Full record

ArticleDer Internist2015

[Type 1 diabetes mellitus. Early detection and prevention].

M Hummel, P Achenbach

Abstract readEnglish Abstract
PubMed Publisher
In one paragraph

Article in Der Internist, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

M HummelDiabetologische Schwerpunktpraxis Rosenheim, Max-Josefs-Platz 21, 83022, Rosenheim, Deutschland, michael.hummel@lrz.uni-muenchen.de.
P Achenbach
Helmholtz Zentrum München · DETechnical University of Munich · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 1 diabetes is the most common autoimmune disease in children and adolescents, with a rising incidence worldwide. Despite improvements in insulin therapy, in many cases complications cannot be avoided and mortality is increased. Therefore, the development of effective prevention strategies is an important medical but also economic goal. Exact prediction of the disease is necessary for prevention studies, and type 1 diabetes can be predicted very accurately with genetic and humoral markers. Primary prevention in genetically predisposed individuals is initiated before diabetes-associated autoantibodies occur. Secondary prevention aims to arrest the progression to type 1 diabetes in autoantibody-positive subjects. Some prevention studies show encouraging results.

Indexed as

Diabetes Mellitus, Type 1Early DiagnosisGenetic MarkersGenetic Predisposition to DiseaseGenetic TestingHLA-A AntigensHumansImmunosuppressive AgentsPrimary PreventionSecondary PreventionGenetic MarkersHLA-A AntigensImmunosuppressive Agents

Identifiers

PMID25894242
OpenAlexW290981437

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.